Gainers

• Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 284.8% to $11.39 during Monday's regular session. The company's market cap stands at $1.9 million.
• Decoy Therapeutics (NASDAQ:DCOY) shares moved upwards by 91.19% to $10.55. The market value of their outstanding shares is at $2.9 million.
• QuidelOrtho (NASDAQ:QDEL) shares rose 33.86% to $18.46. The market value of their outstanding shares is at $939.0 million.
• Atlantic International (NASDAQ:ATLN) shares increased by 30.64% to $1.11. The company's market cap stands at $69.0 million.
• Pulsenmore (NASDAQ:PLSM) stock increased by 27.69% to $7.1. The market value of their outstanding shares is at $36.1 million.
• Tvardi Therapeutics (NASDAQ:TVRD) shares increased by 27.0% to $1.91. The company's market cap stands at $14.0 million.

Losers

• Bluejay Diagnostics (NASDAQ:BJDX) stock declined by 55.3% to $1.31 during Monday's regular session. The company's market cap stands at $3.0 million.
• Evommune (NYSE:EVMN) shares decreased by 37.4% to $15.77. The market value of their outstanding shares is at $906.9 million.
• Creative Medical Tech (NASDAQ:CELZ) shares declined by 27.5% to $0.87. The market value of their outstanding shares is at $4.4 million.
• Jupiter Neurosciences (NASDAQ:JUNS) stock fell 26.29% to $0.21. The market value of their outstanding shares is at $13.5 million.
• Shuttle Pharmaceuticals (NASDAQ:SHPH) stock fell 19.16% to $3.25. The company's market cap stands at $2.3 million.
• China SXT Pharmaceuticals (NASDAQ:SXTC) shares declined by 17.36% to $2.0. The company's market cap stands at $10.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.